Claims
- 1. Indole and indoline compound of the formula: ##STR24## wherein indicates a double bond or a single bond between carbon atoms, R.sup.1 represents hydrogen or alkyl of 1 through 6 carbon atoms and one of the symbols R.sup.2 represents alkyl of 9 through 24 carbon atoms and the other symbol R.sup.2 represents alkyl of 1 through 24 carbon atoms or hydrogen, and R.sup.3 represents alkyl of 1 through 6 carbon atoms or hydrogen, and pharmaceutically acceptable salts thereof.
- 2. Compounds according to claim 1 wherein the group R.sup.1 OOC-- is attached to the 5 or 6 position of the indole or indoline ring system.
- 3. Compounds according to claim 1 wherein R.sup.1 represents hydrogen.
- 4. Compounds according to claim 1, wherein one of the symbols R.sup.2 represents alkyl of 9 through 20 carbon atoms, and the other symbol R.sup.2 represents alkyl of 1 through 24 carbon atoms or hydrogen.
- 5. Compounds according to claim 1 wherein the second symbol R.sup.2 represents hydrogen.
- 6. Compounds according to claim 4 wherein the second symbol R.sup.2 represents alkyl of 1 through 6 carbon atoms.
- 7. Compounds according to claim 1 wherein one of the symbols R.sup.2 represents hydrogen or alkyl of 1 through 5 carbon atoms, and that particular symbol is attached to the 3 position of the indole or indoline ring system.
- 8. Compounds according to claim 7 wherein the symbol R.sup.2 attached to the 3 position of the indole or indoline ring system represents methyl.
- 9. Compounds according to claim 1, wherein R.sup.1 represents methyl, ethyl, butyl, 2,3-dihydroxyprop-1-yl, allyl or pivaloyloxymethyl.
- 10. Compounds according to claim 1 wherein the symbol R.sup.3 in the formula depicted in claim 1 represents hydrogen.
- 11. Indole and indoline compound according to claim 1 of the formula: ##STR25## wherein indicates a double bond or a single bond between carbon atoms, the group R.sup.1 OOC-- is attached to the 5 or 6 position of the indole or indoline ring system, R.sup.1 represents alkyl of 1 through 6 carbon atoms or hydrogen, and one of the symbols R.sup.2' represents alkyl of 9 through 24 carbon atoms and the other symbol R.sup.2' represents alkyl of 1 through 24 carbon atoms, and pharmaceutically acceptable salts thereof.
- 12. Compounds according to claim 11 wherein R.sup.1 represents hydrogen.
- 13. Compounds according to claim 11 wherein one of the symbols R.sup.2' represents alkyl of 9 through 20 carbon atoms, and the other symbol R.sup.2' represents alkyl of 1 through 24 carbon atoms.
- 14. Compounds according to claim 11, wherein the second symbol R.sup.2' represents alkyl, of 1 through 5 carbon atoms and that particular symbol is attached to the 3 position of the indole or indoline ring system.
- 15. Indole and indoline compound according to claim 1 of the formula: ##STR26## wherein indicates a double bond or a single bond between carbon atoms, the group R.sup.1 OOC-- is attached to the 5 or 6 position of the indole or indoline ring system, R.sup.1 represents alkyl of 1 through 6 carbon atoms or hydrogen, and R.sup.2 represents alkyl of 9 through 24 carbon atoms, and pharmaceutically acceptable salts thereof.
- 16. Compounds according to claim 15 wherein R.sup.1 represents hydrogen.
- 17. Compounds according to claim 15 wherein R.sup.2 represents alkyl or 9 through 20 carbon atoms.
- 18. Compound according to claim 11, wherein R.sup.1 represents methyl, ethyl or butyl.
- 19. 2-(n-Octadecyl)indole-5-carboxylic acid and pharmaceutically acceptable salts thereof.
- 20. 2-(n-Undecyl)indole-6-carboxylic acid and pharmaceutically acceptable salts thereof.
- 21. 2-(n-Pentadecyl)indole-5-carboxylic acid and pharmaceutically acceptable salts thereof.
- 22. 2-(n-Undecyl)indole-5-carboxylic acid and pharmaceutically acceptable salts thereof.
- 23. 2-(n-Pentadecyl)indole-6-carboxylic acid and pharmaceutically acceptable salts thereof.
- 24. 2-(1-Methyldecyl)indole-6-carboxylic acid and pharmaceutically acceptable salts thereof.
- 25. 2-(n-Undecyl)indoline-5-carboxylic acid and pharmaceutically acceptable salts thereof.
- 26. 2-(n-Decyl)indoline-5-carboxylic acid and pharmaceutically acceptable salts thereof.
- 27. 2-(n-Undecyl)indoline-6-carboxylic acid and pharmaceutically acceptable salts thereof.
- 28. 2-(n-Undecyl)-3-methylindoline-6-carboxylic acid and pharmaceutically acceptable salts thereof.
- 29. 2-n-Heptadecylindole-5-carboxylic acid.
- 30. 2-n-Dodecylindole-6-carboxylic acid.
- 31. 2-n-Hexadecylindole-5-carboxylic acid.
- 32. Indole and indoline compound of the formula: ##STR27## wherein indicates a double bond or a single bond between carbon atoms, R.sup.1 represents alkyl of 1 through 6 carbon atoms substituted by one or more than one of the same type of substituents selected from the hydroxy group, alkenyl groups of 2 through 5 carbon atoms, and alkanoyloxy groups of 2 through 7 carbon atoms, and one of the symbols R.sup.2 represents alkyl of 7 through 24 carbon atoms and the other symbol R.sup.2 represents alkyl of 1 through 24 carbon atoms or hydrogen, and R.sup.3 represents alkyl of 1 through 6 carbon atoms or hydrogen, and pharmaceutically acceptable salts thereof.
- 33. Compounds according to claim 32 wherein R.sup.1 represents 2,3-dihydroxyprop-1-yl, allyl or pivaloyloxymethyl.
- 34. A pharmaceutical composition useful as a hypolipidaemic agent which comprises, as active ingredient, an effective amount of an indole or indoline compound of the formula: ##STR28## wherein indicates a double bond or a single bond between carbon atoms, R.sup.1 represents hydrogen, alkyl of 1 through 6 carbon atoms, or alkyl of 1 through 6 carbon atoms substituted by one or more than one of the same type of substituents selected from the hydroxy group, alkenyl groups of 2 through 5 carbon atoms, and alkanoyloxy groups of 2 through 7 carbon atoms, and one of the symbols R.sup.2 represents alkyl of 7 through 24 carbon atoms and the other symbol R.sup.2 represents alkyl of 1 through 24 carbon atoms or hydrogen, and R.sup.3 represents alkyl of 1 through 6 carbon atoms or hydrogen, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
Priority Claims (1)
Number |
Date |
Country |
Kind |
8019948 |
Jun 1980 |
GBX |
|
Parent Case Info
This is a continuation of application Ser. No. 274,211 filed June 16, 1981, now abandoned.
US Referenced Citations (7)
Non-Patent Literature Citations (3)
Entry |
Z. Esayan et al., Chem. Abstracts, 72:21657W (1970). |
Z. Esayan et al., Chem. Abstracts, 70:11476f (1969). |
Zh Akopyan et al., Chem. Abstracts, 81:169387q (1974). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
274211 |
Jun 1981 |
|